{"id":3396,"date":"2025-07-01T16:29:20","date_gmt":"2025-07-01T08:29:20","guid":{"rendered":"https:\/\/bccmedianews.com\/?p=3396"},"modified":"2025-07-02T16:36:36","modified_gmt":"2025-07-02T08:36:36","slug":"chinas-innovative-drug-sector-plum-blossoms-emerge-from-bitter-winter","status":"publish","type":"post","link":"https:\/\/bccmedianews.com\/?p=3396","title":{"rendered":"China\u2019s Innovative-Drug Sector: Plum Blossoms Emerge From Bitter Winter"},"content":{"rendered":"\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>Introduction:<\/strong><br>Compared with the industry lull of 2024, the first half of 2025 saw an undeniable volcanic eruption in China\u2019s innovative-drug arena: in Q1 alone, the aggregate value of Chinese pharma cross-border out-licensing deals already equaled the full-year total for 2023. At the 2025 ASCO meeting, Chinese powerhouses\u2014led by Innovent\u2014delivered an impressive report card. China\u2019s drug innovators are shaking off their \u201cfast-follower\u201d stereotype; their startling creativity has international giants such as Pfizer, AstraZeneca, and Merck on a buying spree in China.<\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>1. Policy &amp; Regulation: A Full-Chain Support System Takes Shape<\/strong><\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>Review &amp; approval: the \u201c30-Day Revolution\u201d<\/strong><br>In June, NMPA launched a <strong>30-day fast track<\/strong> for clinical-trial applications covering Category 1 first-in-class drugs, rare-disease therapies, and globally synchronized projects. The timeline shrinks from 60 days to 30, provided companies pledge to start trials within 12 weeks\u2014speeding R&amp;D by roughly <strong>40 percent<\/strong>. On 29 May alone the NMPA cleared <em>eleven<\/em> new drugs (including eight Category 1s), underscoring the efficiency sea-change.<\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>Reimbursement: dual-track breakthrough<\/strong><br>The National Healthcare Security Administration unveiled a \u201c1 + 3 + N\u201d multilevel payment system:<\/p>\n\n\n\n<ul style=\"font-size:20px\" class=\"wp-block-list has-open-sans-font-family\">\n<li><strong>Basic medical-insurance dynamic expansion:<\/strong> 91 drugs (including 38 global first-in-class) will be added to the 2025 list.<\/li>\n\n\n\n<li><strong>Commercial-insurance Class-C catalogue:<\/strong> for the first time, an independent list for private health-insurance coverage of high-value oncology and rare-disease drugs\u2014set to launch in September\u2014offers incremental payment channels for drug makers.<\/li>\n\n\n\n<li><strong>Local pilot programs:<\/strong> Guangzhou, for example, grants national tender drugs standalone budgets, higher reimbursement ratios, and waives outpatient caps, easing the \u201chospital-entry bottleneck.\u201d<\/li>\n<\/ul>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>Global convergence<\/strong><br>New data-exclusivity rules grant up to <strong>six years<\/strong> of protection for originator drugs. Beijing, Shenzhen, and other hubs have compressed trial-start timelines to <strong>20 weeks<\/strong>, with 90 percent ethics-review mutual recognition.<\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>2. Product Launches: A Surge of Home-grown \u201cGlobal Firsts\u201d<\/strong><\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\">By end-June 2025, the NMPA had cleared <strong>38 innovative drugs<\/strong> (including four TCM innovations) spanning oncology, metabolic, and autoimmune diseases. On 29 May alone it set a one-day record of eleven approvals, e.g.:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-open-sans-font-family\" style=\"font-size:20px\"><strong>Famitinib malate<\/strong> (Hengrui): a multikinase TKI, now approved with camrelizumab for platinum-failed, bevacizumab-na\u00efve recurrent or metastatic cervical cancer.<\/li>\n\n\n\n<li class=\"has-open-sans-font-family\" style=\"font-size:20px\"><strong>Phosphorolapitant palonosetron injection<\/strong> (brand: <em>Ruitan Ning<\/em>, Hengrui subsidiary Sundia): prevention of acute &amp; delayed CINV with HEC.<\/li>\n\n\n\n<li class=\"has-open-sans-font-family\" style=\"font-size:20px\"><strong>Rikang trastuzumab emtansine<\/strong> (brand: <em>Avida<\/em>, SHR-A1811, HER2-ADC, Hengrui\/Sundia): conditionally approved for HER2-mutant unresectable or metastatic NSCLC after \u22651 systemic therapy.<\/li>\n\n\n\n<li class=\"has-open-sans-font-family\" style=\"font-size:20px\"><strong>Lovometinib tablets<\/strong> (brand: <em>Fumaining<\/em>, MEK1\/2 inhibitor, Fosun): approved for adult LCH\/histiocytic tumors and pediatric NF1-PN (\u22652 y).<\/li>\n\n\n\n<li class=\"has-open-sans-font-family\" style=\"font-size:20px\"><strong>Fuvixilimab citrate capsules<\/strong> (brand: <em>Futuoning<\/em>, CDK4\/6 inhibitor, Fosun subsidiary Aohong): with fulvestrant for HR+ \/ HER2- metastatic breast cancer progressing on endocrine therapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>3. Corporate Moves: From \u201cTech Export\u201d to \u201cEcosystem Co-creation\u201d<\/strong><\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>License-out 3.0 era<\/strong>\u2014Q1 2025 cross-border deals hit <strong>USD 36.9 billion<\/strong>. Structures are shifting from regional rights sales to global co-development:<\/p>\n\n\n\n<ul style=\"font-size:20px\" class=\"wp-block-list has-open-sans-font-family\">\n<li><strong>Hansoh Pharma \u201cdual stars go global\u201d<\/strong>\n<ul class=\"wp-block-list\">\n<li><em>HS-20094<\/em> GLP-1\/GIP bispecific licensed globally (ex-Greater China) to Regeneron: <strong>USD 80 million<\/strong> upfront + <strong>USD 1.93 billion<\/strong> milestones.<\/li>\n\n\n\n<li>Pre-clinical oral GLP-1 <em>HS-10535<\/em> snapped up by Merck: <strong>USD 112 million<\/strong> upfront + <strong>USD 1.9 billion<\/strong> milestones.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>3SBio smashes upfront record<\/strong><br>PD-1\/VEGF bispecific <em>SSGJ-707<\/em> licensed to Pfizer for <strong>USD 6.05 billion<\/strong> total, with <strong>USD 1.25 billion<\/strong> upfront.<\/li>\n\n\n\n<li><strong>CStone \u201cborrows big ships\u201d<\/strong><br>Sugelezumab (PD-L1) after US\/EU approvals now sublicensed to Latin-American leader SteinCares for ten countries via upfront + milestones + supply revenue.<\/li>\n\n\n\n<li><strong>CSPC \u201cpipeline securitization\u201d<\/strong>\n<ul class=\"wp-block-list\">\n<li>30 May: negotiating three deals worth <strong>~USD 5 billion<\/strong> covering EGFR-ADC, etc.<\/li>\n\n\n\n<li>13 Jun: research pact with AstraZeneca\u2014USD 110 million upfront + up to USD 1.62 billion R&amp;D milestones + USD 3.6 billion sales milestones.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>4. R&amp;D Progress: From \u201cData Export\u201d to \u201cStandard Setting\u201d<\/strong><\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>ASCO: rise of China<\/strong><br>The 2025 ASCO meeting featured <strong>73 Chinese studies<\/strong> in oral sessions (vs. only one in 2015) and <strong>11 late-breaking abstracts<\/strong>. Innovent\u2019s PD-1\/IL-2 bispecific <em>IBI363<\/em> showed 12-month OS of <strong>70.9 percent<\/strong> at 3 mg\/kg in advanced NSCLC\u2014data poised to redefine global oncology standards.<\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>Guidelines &amp; dual filings<\/strong><\/p>\n\n\n\n<ul style=\"font-size:20px\" class=\"wp-block-list has-open-sans-font-family\">\n<li>CStone\u2019s sugelezumab gained ESMO guideline endorsement as a first-line NSCLC option\u2014the first Chinese PD-L1 drug in an intl guideline.<\/li>\n\n\n\n<li>CSPC\u2019s <em>SYH2059<\/em> tablets received both US and China IND clearances for interstitial lung disease.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>5. Conclusion<\/strong><\/p>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\">Key traits of China\u2019s innovative-drug sector in 1H 2025:<\/p>\n\n\n\n<ol start=\"1\" style=\"font-size:20px\" class=\"wp-block-list has-open-sans-font-family\">\n<li><strong>Policy-driven boom<\/strong>\u2014review, payment, and data-protection reforms form a full-chain support ecosystem.<\/li>\n\n\n\n<li><strong>Globalization leap<\/strong>\u2014license-out shifts from volume growth to value escalation (high-value targets, mega-deals).<\/li>\n\n\n\n<li><strong>Clinical impact<\/strong>\u2014stronger data output on international stages like ASCO aligns domestic R&amp;D with global standards.<\/li>\n<\/ol>\n\n\n\n<figure class=\"wp-block-image size-large\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"640\" height=\"259\" data-attachment-id=\"1065\" data-permalink=\"https:\/\/bccmedianews.com\/?attachment_id=1065\" data-orig-file=\"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?fit=1178%2C476&amp;ssl=1\" data-orig-size=\"1178,476\" data-comments-opened=\"0\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"introduce_Micheal Wang\" data-image-description=\"\" data-image-caption=\"\" data-large-file=\"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?fit=640%2C259&amp;ssl=1\" src=\"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?resize=640%2C259&#038;ssl=1\" alt=\"\" class=\"wp-image-1065\" srcset=\"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?resize=1024%2C414&amp;ssl=1 1024w, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?resize=300%2C121&amp;ssl=1 300w, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?resize=768%2C310&amp;ssl=1 768w, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2024\/10\/introduce_Micheal-Wang.png?w=1178&amp;ssl=1 1178w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/figure>\n\n\n\n<p class=\"has-open-sans-font-family wp-block-paragraph\" style=\"font-size:20px\"><strong>[Disclaimer]<\/strong>: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Introduction:Compared with the industry lull of 2024, t [&hellip;]<\/p>\n","protected":false},"author":256241814,"featured_media":3397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":false},"categories":[132842,132876,132846,132860,132844],"tags":[],"class_list":["post-3396","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-economy","category-china-focus","category-global-markets","category-market-trends","category-technology"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/07\/pexels-chokniti-khongchum-1197604-2280571-e1751445004954.jpg?fit=1176%2C785&ssl=1","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pg46U3-SM","jetpack-related-posts":[{"id":4825,"url":"https:\/\/bccmedianews.com\/?p=4825","url_meta":{"origin":3396,"position":0},"title":"Autoimmunity: Can a \u201cKing of Drugs\u201d Be Born in China?","author":"revieweditor","date":"2025\u5e7412\u670805\u65e5","format":false,"excerpt":"In November, The Lancet published a paper from Sha\u2026","rel":"","context":"\u5728\u201cBusiness\u201d\u4e2d","block_context":{"text":"Business","link":"https:\/\/bccmedianews.com\/?cat=132842"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/12\/Autoimmunity-e1764920737654.png?fit=1176%2C784&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/12\/Autoimmunity-e1764920737654.png?fit=1176%2C784&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/12\/Autoimmunity-e1764920737654.png?fit=1176%2C784&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/12\/Autoimmunity-e1764920737654.png?fit=1176%2C784&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/12\/Autoimmunity-e1764920737654.png?fit=1176%2C784&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4695,"url":"https:\/\/bccmedianews.com\/?p=4695","url_meta":{"origin":3396,"position":1},"title":"A Fierce Flu Season Arrives, and the 10-Billion-Yuan Market Reignites","author":"revieweditor","date":"2025\u5e7411\u670818\u65e5","format":false,"excerpt":"Recently, many community health service centers in\u2026","rel":"","context":"\u5728\u201cChina Focus\u201d\u4e2d","block_context":{"text":"China Focus","link":"https:\/\/bccmedianews.com\/?cat=132876"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/11\/flu-e1763440385828.png?fit=1176%2C784&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/11\/flu-e1763440385828.png?fit=1176%2C784&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/11\/flu-e1763440385828.png?fit=1176%2C784&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/11\/flu-e1763440385828.png?fit=1176%2C784&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/11\/flu-e1763440385828.png?fit=1176%2C784&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5105,"url":"https:\/\/bccmedianews.com\/?p=5105","url_meta":{"origin":3396,"position":2},"title":"Small nucleic acid drugs: unveiling the grand curtain of a pharmaceutical revolution","author":"revieweditor","date":"2026\u5e7401\u670823\u65e5","format":false,"excerpt":"On January 9, 2026, China\u2019s small nucleic acid dru\u2026","rel":"","context":"\u5728\u201cBusiness\u201d\u4e2d","block_context":{"text":"Business","link":"https:\/\/bccmedianews.com\/?cat=132842"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/01\/small-nucleic-acid-thumbnail-e1769392084833.png?fit=1176%2C784&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/01\/small-nucleic-acid-thumbnail-e1769392084833.png?fit=1176%2C784&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/01\/small-nucleic-acid-thumbnail-e1769392084833.png?fit=1176%2C784&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/01\/small-nucleic-acid-thumbnail-e1769392084833.png?fit=1176%2C784&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/01\/small-nucleic-acid-thumbnail-e1769392084833.png?fit=1176%2C784&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4152,"url":"https:\/\/bccmedianews.com\/?p=4152","url_meta":{"origin":3396,"position":3},"title":"AI Drug Discovery\u2014Pharma Industry Reaches Its \u201cChatGPT Moment\u201d","author":"revieweditor","date":"2025\u5e7410\u670811\u65e5","format":false,"excerpt":"The year 2025 has become a breakout year for AI dr\u2026","rel":"","context":"\u5728\u201cAI &amp; Big Data\u201d\u4e2d","block_context":{"text":"AI &amp; Big Data","link":"https:\/\/bccmedianews.com\/?cat=132868"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/10\/AI-Medicine-e1760082149254.png?fit=1176%2C784&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/10\/AI-Medicine-e1760082149254.png?fit=1176%2C784&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/10\/AI-Medicine-e1760082149254.png?fit=1176%2C784&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/10\/AI-Medicine-e1760082149254.png?fit=1176%2C784&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/10\/AI-Medicine-e1760082149254.png?fit=1176%2C784&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":3214,"url":"https:\/\/bccmedianews.com\/?p=3214","url_meta":{"origin":3396,"position":4},"title":"BNCT: A Tumor-Killing Weapon Ready to Fire","author":"revieweditor","date":"2025\u5e7406\u670806\u65e5","format":false,"excerpt":"Introduction:In 2020, Boron Neutron Capture Therap\u2026","rel":"","context":"\u5728\u201cChina Focus\u201d\u4e2d","block_context":{"text":"China Focus","link":"https:\/\/bccmedianews.com\/?cat=132876"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-2025%EB%85%84-6%EC%9B%94-6%EC%9D%BC-%EC%98%A4%ED%9B%84-12_09_00-e1749179466255.png?fit=1176%2C784&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-2025%EB%85%84-6%EC%9B%94-6%EC%9D%BC-%EC%98%A4%ED%9B%84-12_09_00-e1749179466255.png?fit=1176%2C784&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-2025%EB%85%84-6%EC%9B%94-6%EC%9D%BC-%EC%98%A4%ED%9B%84-12_09_00-e1749179466255.png?fit=1176%2C784&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-2025%EB%85%84-6%EC%9B%94-6%EC%9D%BC-%EC%98%A4%ED%9B%84-12_09_00-e1749179466255.png?fit=1176%2C784&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-2025%EB%85%84-6%EC%9B%94-6%EC%9D%BC-%EC%98%A4%ED%9B%84-12_09_00-e1749179466255.png?fit=1176%2C784&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5530,"url":"https:\/\/bccmedianews.com\/?p=5530","url_meta":{"origin":3396,"position":5},"title":"CMEF: China&#8217;s Medical Device AI Leap","author":"revieweditor","date":"2026\u5e7404\u670814\u65e5","format":false,"excerpt":"At the just-concluded 93rd CMEF (China Internation\u2026","rel":"","context":"\u5728\u201cAI &amp; Big Data\u201d\u4e2d","block_context":{"text":"AI &amp; Big Data","link":"https:\/\/bccmedianews.com\/?cat=132868"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/04\/14edc0e9-53d3-47b5-b2bc-f2a735657367-e1776148149133.jpg?fit=1176%2C784&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/04\/14edc0e9-53d3-47b5-b2bc-f2a735657367-e1776148149133.jpg?fit=1176%2C784&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/04\/14edc0e9-53d3-47b5-b2bc-f2a735657367-e1776148149133.jpg?fit=1176%2C784&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/04\/14edc0e9-53d3-47b5-b2bc-f2a735657367-e1776148149133.jpg?fit=1176%2C784&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/bccmedianews.com\/wp-content\/uploads\/2026\/04\/14edc0e9-53d3-47b5-b2bc-f2a735657367-e1776148149133.jpg?fit=1176%2C784&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/posts\/3396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/users\/256241814"}],"replies":[{"embeddable":true,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3396"}],"version-history":[{"count":5,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/posts\/3396\/revisions"}],"predecessor-version":[{"id":3402,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/posts\/3396\/revisions\/3402"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=\/wp\/v2\/media\/3397"}],"wp:attachment":[{"href":"https:\/\/bccmedianews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bccmedianews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}